ACADIA Pharmaceuticals Inc.
ACAD
Hisse Senetlerindeki Sıralama
#4598
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Hisse Fiyatı
$19.42
Piyasa Değeri
$3.35B
Değişim (1 gün)
1.56%
Değişim (1 yıl)
-7.04%
Ülke
US
Ticaret ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD) için EPS
June 2026 itibariyle EPS TTM: $2.25
ACADIA Pharmaceuticals Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $2.25'dir. 2023 yılı sonunda, şirketin EPS'si $-0.37 idi; bu, 2022 yılındaki EPS olan $-1.34 ile önceki yıla göre azalma.
ACADIA Pharmaceuticals Inc. için 2000 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $2.25 | 64.23% |
| 2024 | $1.37 | -470.27% |
| 2023 | $-0.37 | -72.39% |
| 2022 | $-1.34 | 27.62% |
| 2021 | $-1.05 | -41.34% |
| 2020 | $-1.79 | 11.88% |
| 2019 | $-1.60 | -17.53% |
| 2018 | $-1.94 | -17.80% |
| 2017 | $-2.36 | 0.85% |
| 2016 | $-2.34 | 43.56% |
| 2015 | $-1.63 | 71.58% |
| 2014 | $-0.95 | 115.91% |
| 2013 | $-0.44 | 15.79% |
| 2012 | $-0.38 | -13.64% |
| 2011 | $-0.44 | -212.82% |
| 2010 | $0.39 | -132.50% |
| 2009 | $-1.20 | -30.64% |
| 2008 | $-1.73 | 8.12% |
| 2007 | $-1.60 | -0.62% |
| 2006 | $-1.61 | 3.87% |
| 2005 | $-1.55 | -38.00% |
| 2004 | $-2.50 | -74.12% |
| 2003 | $-9.66 | 9.03% |
| 2002 | $-8.86 | -25.73% |
| 2001 | $-11.93 | 25.18% |
| 2000 | $-9.53 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | 669.78% |
US
|
|
| $-7.98 | -454.67% |
US
|
|
| $-5.29 | -335.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,132.89% |
NL
|
